Edition:
India

Eloxx Pharmaceuticals Inc (ELOX.OQ)

ELOX.OQ on NASDAQ Stock Exchange Global Market

6.48USD
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
$6.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,759
52-wk High
$18.48
52-wk Low
$5.14

Latest Key Developments (Source: Significant Developments)

Eloxx Pharmaceuticals Says An IND For ELX-02 In Cystic Fibrosis Is Now Open In The U.S.
Wednesday, 31 Jul 2019 

July 31 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS ANNOUNCES OPEN INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR A PHASE 2 CLINICAL TRIAL OF ELX-02 IN CYSTIC FIBROSIS PATIENTS WITH THE G542X MUTATION IN THE US AND PROTOCOL ENDORSEMENT FROM THE CYSTIC FIBROSIS FOUNDATION (CFF).ELOXX PHARMA - ON TRACK TO REPORT DATA FROM PHASE 2 CLINICAL TRIALS FOR ELX-02 IN CYSTIC FIBROSIS & CYSTINOSIS IN U.S., EUROPE, ISRAEL, CANADA IN 2019.  Full Article

Eloxx Pharmaceuticals Presents Positive New Data For Lead Investigational Drug, Elx-02
Thursday, 6 Jun 2019 

June 6 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS PRESENTS POSITIVE NEW DATA FOR LEAD INVESTIGATIONAL DRUG, ELX-02, AT THE 42ND EUROPEAN CYSTIC FIBROSIS SOCIETY CONFERENCE (ECFS).ELOXX PHARMACEUTICALS INC - ELX-02 INCREASES CFTR MRNA TO HEALTHY CONTROL LEVELS.ELOXX PHARMACEUTICALS INC - ELOXX TO REPORT TOP LINE DATA FROM PHASE 2 CLINICAL TRIAL IN CYSTIC FIBROSIS IN 2019.ELOXX PHARMACEUTICALS-PHASE 2 PROTOCOL REVIEWED, APPROVED BY EUROPEAN CYSTIC FIBROSIS SOCIETY-CLINICAL TRIAL NETWORK, GIVEN A SCORE OF "HIGH PRIORITY".ELOXX PHARMACEUTICALS INC - ELX-02 HAS BEEN GENERALLY WELL TOLERATED IN CLINICAL STUDIES TO DATE.ELOXX PHARMACEUTICALS- POSITIVE DATA SHOWS ELX-02 INCREASES FUNCTIONAL CFTR PROTEIN IN ORGANOID, HUMAN BRONCHIAL EPITHELIAL, USSING CHAMBER SYSTEMS.  Full Article

Eloxx Pharmaceuticals Q3 Loss Per Share $0.32
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.32.Q3 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.ON TRACK FOR TOP LINE DATA FROM TWO PHASE 2 CLINICAL TRIALS IN CYSTIC FIBROSIS AND CYSTINOSIS IN 2019.  Full Article

Eloxx Pharmaceuticals Reports Second Quarter 2018 Financial
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.42.Q2 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.CTA APPROVED IN BELGIUM AND IND OPEN IN U.S. FOR INVESTIGATIONAL DRUG CANDIDATE, ELX-02.ON TRACK TO INITIATE PHASE 2 CLINICAL TRIALS IN CYSTIC FIBROSIS AND CYSTINOSIS IN 2018.AS OF JUNE 30, 2018, HAD CASH AND CASH EQUIVALENTS OF $63.4 MILLION.  Full Article

Eloxx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Wednesday, 25 Apr 2018 

April 24 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO OFFER AND SELL 5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Eloxx Pharmaceuticals Reports Full Year 2017 Results
Monday, 19 Mar 2018 

March 19 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS REPORTS FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.  Full Article